HO1 Stock Overview
Engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Hologic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$60.00 |
| 52 Week High | US$76.50 |
| 52 Week Low | US$60.00 |
| Beta | 0.98 |
| 1 Month Change | -14.29% |
| 3 Month Change | -19.46% |
| 1 Year Change | -14.36% |
| 3 Year Change | -4.64% |
| 5 Year Change | 41.51% |
| Change since IPO | 250.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| HO1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -3.2% | -2.4% | -0.6% |
| 1Y | -14.4% | -4.7% | 14.8% |
Return vs Industry: HO1 underperformed the German Medical Equipment industry which returned -4.7% over the past year.
Return vs Market: HO1 underperformed the German Market which returned 14.8% over the past year.
Price Volatility
| HO1 volatility | |
|---|---|
| HO1 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: HO1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine HO1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 7,063 | Steve MacMillan | www.hologic.com |
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Hologic, Inc. Fundamentals Summary
| HO1 fundamental statistics | |
|---|---|
| Market cap | €13.83b |
| Earnings (TTM) | €711.19m |
| Revenue (TTM) | €3.86b |
19.5x
P/E Ratio3.6x
P/S RatioIs HO1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HO1 income statement (TTM) | |
|---|---|
| Revenue | US$4.04b |
| Cost of Revenue | US$1.58b |
| Gross Profit | US$2.46b |
| Other Expenses | US$1.72b |
| Earnings | US$744.00m |
Last Reported Earnings
Dec 28, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.32 |
| Gross Margin | 60.93% |
| Net Profit Margin | 18.42% |
| Debt/Equity Ratio | 52.9% |
How did HO1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 04:15 |
| End of Day Share Price | 2025/02/18 00:00 |
| Earnings | 2024/12/28 |
| Annual Earnings | 2024/09/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hologic, Inc. is covered by 51 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Charles Butler | Barclays |